US2017290702A1PendingUtilityA1
Apparatus and formulations for suprachoroidal drug delivery
Est. expiryFeb 22, 2026(expired)· nominal 20-yr term from priority
A61F 9/007A61F 9/0026A61F 9/0017A61K 9/0051A61K 31/718A61K 9/1635A61K 31/728A61K 9/0048A61K 9/14A61K 31/722A61K 31/737A61K 31/717A61K 47/36A61M 2210/0612A61M 2005/3103A61M 5/486A61F 9/00736A61K 31/716A61K 38/39A61K 9/50
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.
Claims
exact text as granted — not AI-modified1 . A method of administering drugs in the suprachoroidal space of the eye comprising the steps of placing a needle in scleral tissues toward the suprachoroidal space at a depth of at least half of the scleral thickness, and injecting a drug formulation through said needle into the sclera in close proximity to the inner boundary of the sclera such that said formulation dissects the scleral tissues adjacent to said suprachoroidal space and enters said suprachoroidal space.
2 . The method of claim 1 , wherein said formulation enters said suprachoroidal space and flows toward the posterior region of said suprachoroidal space.
3 . A method for administering drugs to an eye comprising injection of a drug formulation into the suprachoroidal space, said drug formulation comprising a biologically active substance and a polymer excipient, wherein the drug formulation forms a layer between the choroid and sclera in the area of administration.
4 . The method according to claim 3 , wherein said injection comprises injection through a needle.
5 . The method according to claim 3 , wherein said biologically active substance comprises a steroid or non-steroidal anti-inflammatory agent to treat inflammation and edema.
6 . The method according to claim 3 wherein said polymer excipient comprises a water soluble polymer.
7 . The method according to claim 1 , wherein the placing of the needle tip is guided by imaging surrounding tissues.
8 . The method according to claim 1 , wherein said needle comprises a sensor to guide the placement of the needle tip.
9 . A method for administering drugs to an eye comprising:
injection of a drug formulation into the suprachoroidal space, said drug formulation comprising microspheres or microparticles with an outer diameter in the range of about 1 to 33 microns, and a polymer excipient,-wherein said microspheres or microparticles comprising a biologically active substance, wherein said polymer excipient acts to uniformly distribute the microspheres or microparticles administered to the suprachoroidal space.
10 . A method for administering drugs to an eye comprising:
injection of a drug formulation into the suprachoroidal space, said drug formulation comprising microspheres or microparticles with an outer diameter in the range of about 1 to 33 microns; wherein said microspheres or microparticles comprise a biologically active substance, wherein said microspheres or microparticles subsequently migrate posteriorly to treat a posterior region distant from the injection site.
11 . The method according to 10 wherein said drug formulation additionally comprises a polymer excipient.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.